Shaoting Zhang

Shaoting Zhang

Auto-generated profile, based on publicly available information

Shaoting Zhang

Department of Urology, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2026 in Prostate International
Verified
Journal Article
Open access
HZHaoyue Zhang
Haoyue Zhang
SZShaoting Zhang
Shaoting Zhang
JCJonathon Rhys Carll
Jonathon Rhys Carll
NLNathan Lawrentschuk
Nathan Lawrentschuk

Verified
Journal Article
Open access
PDF file
HZHaoyue Zhang
Haoyue Zhang
SZShaoting Zhang
Shaoting Zhang
JCJonathon Rhys Carll
Jonathon Rhys Carll
NLNathan Lawrentschuk
Nathan Lawrentschuk
Background/Objectives: Nutraceutical use is common among men with prostate cancer, but its clinical efficacy remains uncertain. We systematically reviewed randomized controlled trials evaluating orally administered nutraceutical and defined dietary interventions after prostate cancer diagnosis. Methods: PubMed, MEDLINE, and Embase were searched through September 2026, and risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Results: Twenty-six trials involving 2188 randomized participants were included. Four were judged to be at low risk of bias, 15 had some concerns, and seven were at high risk. An exploratory random-effects meta-analysis of three soy trials showed no significant difference in post-intervention serum prostate-specific antigen compared with placebo or control (mean difference: −0.50 ng/mL, 95% confidence interval: −2.14 to 1.14; p = 0.55; I2 = 0%). Across the wider evidence base, effects on prostate-specific antigen kinetics, tissue biomarkers, oxidative stress, and inflammatory markers were inconsistent. The available evidence was insufficient to establish a validated benefit for disease progression, metastasis, cancer-specific survival, or overall survival. Conclusions: The current evidence is insufficient to establish a clinically meaningful benefit of nutraceutical or defined dietary interventions in prostate cancer management. Larger, well-designed trials using standardized interventions, clinically meaningful endpoints, and longer follow-up are required.